<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911192</url>
  </required_header>
  <id_info>
    <org_study_id>CDR in PE</org_study_id>
    <nct_id>NCT04911192</nct_id>
  </id_info>
  <brief_title>Catheter-Directed Pulmonary Reperfusion in Treatment of Pulmonary Embolism Patients</brief_title>
  <official_title>Catheter-Directed Pulmonary Re Perfusion in Treatment of Intermediate and High Risk Pulmonary Embolism Patients and Its Impact on Pulmonary Artery Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Primary objective: to evaluate the success and mortality rates of catheter-directed&#xD;
           reperfusion therapy in comparison to traditional use of systemic intravenous&#xD;
           fibrinolytic therapy, will focus at safety of such management measured by in-hospital&#xD;
           mortality and prevalence of severe adverse events.&#xD;
&#xD;
        -  Secondary objective: to assess the feasibility of catheter-directed reperfusion in&#xD;
           management of intermediate and high risk pulmonary embolism in Assiut University&#xD;
           hospital and its reflection on pulmonary artery pressure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolic disease represents one of the most important causes of cardiovascular&#xD;
      death in the world. Symptomatic pulmonary embolism (PE) occurs in about 500,000 patients&#xD;
      annually, with an estimated mortality as high as 30% in high-risk patients .&#xD;
&#xD;
      High-risk pulmonary embolism clinically manifests with hemodynamic instability and systemic&#xD;
      hypotension (systolic blood pressure &lt; 90 mm Hg, pressure drop of more than 40 mm Hg or&#xD;
      requiring administration of inotropic agents. In this form of PE (pulmonary embolism) imaging&#xD;
      studies usually reveal a &quot;saddle embolus&quot; at the bifurcation of the pulmonary trunk, embolism&#xD;
      of the main pulmonary artery, or embolic occlusion of at least two lobar arteries.&#xD;
&#xD;
      Mortality in high-risk pulmonary embolism is at the level of 60%, and in 66% of these&#xD;
      patients fatal outcomes take place during the first hours from the onset of clinical&#xD;
      symptoms. The remaining patients with severe pulmonary embolism , those with intermediate&#xD;
      risk of mortality, do not reveal hypotension, but present with clinical symptoms comprising&#xD;
      dyspnea and/or tachycardia. Estimated 30-day mortality in patients with intermediate risk PE&#xD;
      (pulmonary embolism) is at the level of 15-20%, and these patients are at a risk of&#xD;
      developing pulmonary hypertension and right ventricle heart failure. Given the fact that 40%&#xD;
      of patients with class 4 or 5 of the Pulmonary Embolism Severity Index present with&#xD;
      contraindications for systemic fibrinolytic therapy, Catheter-directed reperfusion therapy&#xD;
      seems to be a promising alternative treatment modality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of mortality (mortality rate)</measure>
    <time_frame>30-day</time_frame>
    <description>number of deaths from total number of patients in each arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>7 days</time_frame>
    <description>as major and minor bleedings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Success</measure>
    <time_frame>2 weeks</time_frame>
    <description>number of cases with clinical success which defined as stabilization of hemodynamic parameters, resolution of hypoxia, survival from PE(pulmonary embolism) and restoring of right ventricular function (improvement of ghit ventricle and pulmonary artery pressure and decrease troponin level)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Changes in mean blood pressure</measure>
    <time_frame>Baseline (measured at first admission) and compared with measurements the following second, eighth, and 24th hours of the intervention.</time_frame>
    <description>the percent of change in mean arterial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulmonary artery pressure</measure>
    <time_frame>Baseline (at addmission) and 24 hours after catheter-directed intervention</time_frame>
    <description>Mean pulmonary artery pressure will be estimated by transthoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU(intensive care unit) stay</measure>
    <time_frame>&quot;through study completion, an average of 1 year&quot;.</time_frame>
    <description>the duration of ICU (intensive care unit) stay by days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>&quot;through study completion, an average of 1 year&quot;.</time_frame>
    <description>the duration of hospital stay by days</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>systemic thrombolysis group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mechanical fragmentation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In Situ thrombolysis group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mechanical fragmentation</intervention_name>
    <description>patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy</description>
    <arm_group_label>mechanical fragmentation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In Situ thrombolysis</intervention_name>
    <description>Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).</description>
    <arm_group_label>In Situ thrombolysis group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years old.&#xD;
&#xD;
          -  Both gender males and females.&#xD;
&#xD;
          -  Patients with angiographically confirmed acute high risk pulmonary embolism with shock&#xD;
             index &gt;1.&#xD;
&#xD;
          -  pulmonary arterial occlusion with &gt;50% involvement of the central (main and/or lobar)&#xD;
             pulmonary, and dysfunction of the right ventricle and elevated troponin.&#xD;
&#xD;
          -  patients with high risk pulmonary embolism who remain unstable after receiving&#xD;
             fibrinolysis&#xD;
&#xD;
          -  patients with high risk PE pulmonary embolism who cannot receive fibrinolysis&#xD;
&#xD;
          -  patients with intermediate high risk PE pulmonary embolism with adverse prognosis (new&#xD;
             hemodynamic instability, worsening respiratory failure, severe RV (right ventricle)&#xD;
             dysfunction, or major myocardial necrosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with echocardiographically confirmed right sided thrombi.&#xD;
&#xD;
          -  patients with low-risk PE pulmonary embolism or submassive acute PE pulmonary embolism&#xD;
             with minor RV (right ventricle) dysfunction, minor myocardial necrosis, and no&#xD;
             clinical worsening&#xD;
&#xD;
          -  Anaphylactic reaction to contrast media.&#xD;
&#xD;
          -  Acute renal failure or severe chronic non-dialysis dependent kidney disease.&#xD;
&#xD;
          -  Uncooperative patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed M abd el hadi, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor of chest diseases and tuberculosis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman k hassan, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>olfat M El shinnawy, prof</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aliaa S Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aliaa Ahmed, MD</last_name>
    <phone>201009087704</phone>
    <email>aliaasalama49@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arafa abo el Hassan, lecturer</last_name>
    <phone>201017445151</phone>
    <email>arafaelkady@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756-64.</citation>
    <PMID>17938798</PMID>
  </reference>
  <reference>
    <citation>Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999 Apr 24;353(9162):1386-9.</citation>
    <PMID>10227218</PMID>
  </reference>
  <reference>
    <citation>Nassiri N, Jain A, McPhee D, Mina B, Rosen RJ, Giangola G, Carroccio A, Green RM. Massive and submassive pulmonary embolism: experience with an algorithm for catheter-directed mechanical thrombectomy. Ann Vasc Surg. 2012 Jan;26(1):18-24. doi: 10.1016/j.avsg.2011.05.026. Epub 2011 Aug 31.</citation>
    <PMID>21885244</PMID>
  </reference>
  <reference>
    <citation>Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007 Sep;82(9):777-82.</citation>
    <PMID>17626254</PMID>
  </reference>
  <reference>
    <citation>Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Gali√® N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. Erratum in: Eur Heart J. 2015 Oct 14;36(39):2666. Eur Heart J. 2015 Oct 14;36(39):2642.</citation>
    <PMID>25173341</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aliaa Salama Ahmed Omar</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

